Skip to main content
Ab&B Bio-Tech CO., LTD. JS logo

Ab&B Bio-Tech CO., LTD. JS — Investor Relations & Filings

Ticker · 2627 ISIN · CNE1000071P9 HKEX Manufacturing
Open in API
Filings indexed 60 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2627

About Ab&B Bio-Tech CO., LTD. JS

http://www.abbbio.com

Ab&B Bio-Tech CO., LTD. JS is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of human vaccines and biological preparations that confer active immunity. The company's mission centers on developing globally innovative vaccines and utilizing new technologies to improve traditional vaccines. Its comprehensive pipeline targets infectious diseases and includes candidates across viral, bacterial, conjugate, subunit, and mRNA platforms. The primary commercial product is the Quadrivalent Subunit Influenza Vaccine, approved for individuals aged six months and above. Advanced pipeline assets, such as the 23-valent Pneumococcal Polysaccharide Vaccine and the Freeze-dried Human Rabies Vaccine (Human Diploid Cell), have completed Phase I clinical trials. R&D operations are supported by facilities in Shanghai and Taizhou, with the company emphasizing scientific validation through publications in international journals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT)
Regulatory Filings Classification · 60% confidence The document is a voluntary announcement by Ab&B Bio-Tech regarding the commencement of Phase I and Phase II clinical trials for a vaccine. It contains no financial data, no management changes, no voting results, no capital transactions, no legal proceedings or M&A activity. It is a corporate update required under listing rules but does not fit any specialized category (e.g., earnings, interim report, board changes). Therefore it defaults to the general regulatory/announcement category: RNS.
2026-05-13 English
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA RSV VACCINE
Regulatory Filings
2026-05-08 English
FORM OF PROXY FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 TO BE HELD ON WEDNESDAY, MAY 27, 2026 AND ANY ADJOURNMENT THEREOF
Regulatory Filings
2026-05-08 English
(1) ABOLITION OF THE SUPERVISORY COMMITTEE (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION (3) AMENDMENTS TO CERTAIN INTERNAL CORPORATE GOVERNANCE POLICIES (4) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE D
Regulatory Filings
2026-05-08 English
NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026
Regulatory Filings
2026-05-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 April 2026. It contains detailed information on movements in authorised/registered share capital, issued shares, treasury shares, public float sufficiency confirmation, and confirmations pursuant to specific listing rules of The Stock Exchange of Hong Kong Limited. The document is a regulatory submission reporting monthly share capital and shareholding movements, not a financial report, earnings release, or management discussion. It is a regulatory filing required by the exchange to ensure compliance with listing rules regarding share capital and public float. The document length is 9468 characters, which is substantive but the content is clearly a regulatory compliance report rather than a financial or management report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-04 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.